EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Summary

The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B. This Phase 1 study is designed primarily to assess Pharmacokinetics (PK) under fed and fasted conditions, and to assess the safety, tolerability and Pharmacodynamics (PD) of single oral doses of EYP001a in subjects with chronic HBV infection.

Timeline

Start

2017-02-10

Primary completion

2017-10-12

Completion

2017-10-12

Drugs

Indications